Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK (sodium thiosulfate anhydrous injection) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of PEDMARK as a chemoprotectant and is developing PEDMARK as a protectant against the hearing loss caused by platinum-based anti-cancer agents in children. The FENC stock yearly return is shown above.
The yearly return on the FENC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FENC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|